An observational study in Asthma, sponsored by Xijing Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-29.
Sponsored by Xijing Hospital · Observational
Program： Clinical Study of Relationship Between Granulocyte Activation, HDAC2 and Severe Asthma Aim：The early prediction of severe asthma, early intervention on the disease, reduce the family and the national finance.
design:This study is a single center randomized controlled trial designed by the Department of respiratory medicine, Xijing Hospital, as the main research unit.Compare the case group(severe asthma group and mild-and-moderate asthma group) and control group(healthy control group) by detecting the activity of MPO、NE、MMP-9 and ECP in the peripheral blood and the activity of HDAC2 in PBMCs of patients.
case:60
Case selection:
Inclusion criteria: age 18-75 years old; diagnosis of asthma was clear; informed consent was signed.
Exclusion criteria: poor compliance; cognitive ability is low; psychiatric disorders need to be combined with psychotropic medication.
Application of SPSS 19 statistical software. Measurement data were expressed as mean ± standard deviation.
First the data is normality tested and homogeneity of variance tested, according to the measurement data of normal distribution by SNK single factor analysis of variance; does not conform to the normal distribution of measurement data, using the Kruskal Wallis non parametric test. P \< 0.05 for the difference was statistically significant.
3,921 studies on the registry are indexed under Asthma; 506 are open to participants now.
This study's planned enrollment of 60 is below the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
outpatients and the students
inclusion criteria: healthy control group：
In the past 1 year need guidelines of global asthma record instrument 4-5 drug treatment of asthma [high dose inhaled corticosteroid with long-acting beta2 receptor agonist or leukotriene modifiers / theophylline or systemic hormone therapy is more than or equal to 50% of the time, in order to prevent into uncontrolled asthma, or even in the treatment is to control asthma patients for severe asthma.
exclusion criteria：
Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
Other: severe asthma group
No intervention
Evidence of clinically definite severe asthma confirmed by the plasma concentration of blood related indexes(MPO、MMP-9、NE、ECP、HDAC2)
Compare the difference was not statistically significant of the different groups by testing the concentration of blood related indicators of subjects
Time frame: one year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital